Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval

Blood Cancer J. 2024 Mar 18;14(1):47. doi: 10.1038/s41408-024-01029-3.

Authors

Ayalew Tefferi¹, Animesh Pardanani²

Affiliations

¹ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA. tefferi.ayalew@mayo.edu.
² Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

No abstract available

Publication types

Editorial

MeSH terms

Benzamides
Clinical Trials as Topic
Humans
Janus Kinase 2
Primary Myelofibrosis* / drug therapy
Protein Kinase Inhibitors
Pyrimidines / therapeutic use

Substances

Benzamides
Janus Kinase 2
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
Protein Kinase Inhibitors
Pyrimidines